← All trials
NCT04810091
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 18, 2021
- Primary completion
- Aug 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- Mar 22, 2021
- Last posted
- Aug 24, 2021
- Enrollment
- 60
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.